Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivantinib + cetuximab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tivantinib + cetuximab is an investigational **combination regimen** involving tivantinib, a selective small molecule inhibitor of the MET receptor tyrosine kinase, and cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR). This combination has been studied primarily for the treatment of EGFR inhibitor-resistant, MET-high, KRAS wild-type metastatic colorectal cancer (mCRC) and recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Tivantinib inhibits MET-dependent signaling, a pathway implicated in tumor growth and resistance to EGFR-targeted therapies, while cetuximab inhibits EGFR-driven proliferation. The rationale for this combination is to overcome resistance to EGFR blockade by simultaneous inhibition of both MET and EGFR pathways[3][4][5].
- Brand names
- Erbitux
- Other names
- ARQ197ARQ-197ARQ 197tivantinibcetuximab
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on tivantinib + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivantinib + cetuximab.